logo of the vendor
Pharma Intelligence UK Ltd logo

Advances and opportunities in Liver Cancer research

thumbnail of content

Liver cancer is one of the leading causes of cancer death, with new cases predicted to rise by an alarming 70% by the time we reach 2025 (vs. 2022). Hepatocellular carcinoma, or HCC, accounts for 90% of cases, and poses significant challenges in treatment. Access this in-depth report to explore the global drug development landscape, and how promising advances in treatments are providing hope for the future. Explore topics including:

  • Evolution of treatments - from traditional chemotherapy to targeted therapies, immunotherapy and transarterial therapies
  • Global clinical trial landscape, including stats on patient recruitment, trial density and growth trends by region
  • Role of public and venture capital funding
  • Future innovations and collaboration boosting survival rates
  • SWOT analysis on LC management

Read the Report

Opt In?

Please complete all required fields to access the content!

Explore similar content

ThermoFisher
Pharma Intelligence UK Ltd

Securing your samples: Strategies for safeguarding critical biological materials

To deliver these therapies to the patients who need them, their success hinges on effective storage and management to maintain integrity throughout their lifecycle. From early development to commercialization, safeguarding sensitive biological materials demands scalable storage solutions and meticulous risk mitigation strategies. Partnering with a CDMO specializing in ultracold storage and biorepository management is critical to preserving product integrity and ensuring continuity throughout every development stage. This webinar will explore how the right CDMO partner can streamline biological material storage, mitigate risks, and provide the scalability needed to support growth from clinical trials to commercial launch, empowering you to advance your pipeline with confidence. Participants will gain insight into:
Webinar Clinical Studies Pharmaceutical Research and Development
IQVIA Technologies
Pharma Intelligence UK Ltd

A New Era of Participant Payment Services

Financial burdens are cited as one of the main barriers to clinical trial recruitment and retention, with traditional methods proving unreliable, complicated and slow. For trial sites and sponsors, the administration burden can be overwhelming, especially on a global scale. Discover how IQVIA’s Participant Payment service is transforming the participant payment landscape, simplifying the process and driving clinical trial success, by offering:
Article Clinical Studies Pharmaceutical Research and Development
Novotech
Pharma Intelligence UK Ltd

From biomarkers to regulatory compliance, and the impact of AI/ML

The field of precision medicine is rapidly evolving, enabling the development of innovative therapies highly tailored to individuals’ genetic profiles - resulting in revolutionized treatments and improved patient outcomes. Discover expert insights on the current landscape of personalized medicine, including the opportunities and challenges, including:
Report Clinical Studies Pharmaceutical Research and Development